Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970336 | 0.89 | FOLH1 (0.36) | FOLH1GNPATADRA1A | |
| SCHEMBL19975584 | 0.89 | FOLH1 (0.36) | FOLH1GNPATADRA1A | |
| SCHEMBL19975587 | 0.88 | GNPAT (0.37) | FOLH1SMN1; SMN2GNPATADRA1A | |
| SCHEMBL21032104 | 0.87 | GLP1R (0.41) | FOLH1ALB | |
| SCHEMBL21534104 | 0.85 | GLP1R (0.48) | FOLH1 | |
| SCHEMBL21534085 | 0.84 | FOLH1 (0.35) | FOLH1SMN1; SMN2 | |
| SCHEMBL21031586 | 0.83 | FOLH1 (0.47) | FOLH1GNPAT | |
| SCHEMBL21032263 | 0.79 | FOLH1 (0.60) | FOLH1 | |
| SCHEMBL13914133 | 0.79 | FOLH1 (0.49) | FOLH1SIRT5SMN1; SMN2ADRA1A | |
| SCHEMBL19975586 | 0.74 | CTSK (0.34) | GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617662-B2 | Autophagy activation-induced compound for improving skin inflammation for aging | INCOSPHARM CORPORATION (KR) | 2020-04-14 | — | — | US | disclosed |
| US-20190160033-A1 | NOVEL AUTOPHAGY ACTIVATION-INDUCED COMPOUND FOR IMPROVING SKIN INFLAMMATION FOR AGING | INCOSPHARM CORPORATION (KR) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617662-B2 | Autophagy activation-induced compound for improving skin inflammation for aging | TFEB, ATG7, BECN1 | FOLH1 4203/4885SIRT5 1418/4885SMN1; SMN2 2443/4885 |
| US-20190160033-A1 | NOVEL AUTOPHAGY ACTIVATION-INDUCED COMPOUND FOR IMPROVING SKIN INFLAMMATION FOR AGING | TFEB, ATG7, BECN1 | FOLH1 3707/4885SIRT5 1627/4885SMN1; SMN2 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.